Immedica announces that Loargys® receives positive opinion by the CHMP

PharmaMar (MSE:PHM) has announced today that it has signed an agreement with Immedica Pharma AB (Immedica) for the exclusive distribution and marketing, if approved, of the anti-tumor drug lurbinectedin for territories that include the UK, Ireland, the Nordic countries, some countries within Eastern Europe, the Middle East and North Africa.

Read more

News

Impilo Closes €320m Single Asset Continuation Fund Transaction to Support the Continued Growth of Immedica Pharma

On 20th September 2024, Impilo, a Nordic healthcare investment firm and KKR, a leading global investment firm, announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm, focused on the commercialization of medicines for rare diseases and specialty care products.

Read article

Impilo and KKR Completes Joint Acquisition of Immedica Pharma

Stockholm and London, 19 September 2024 – KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have today announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm and focused on the commercialization of medicines for rare diseases and specialty care products.

Read article

Scantox Group acquires Gentronix

Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization (“CRO”),  well recognized for its high-quality genetic toxicology services and strong scientific engagement.

Read article